The effect of your Irbesartan drug in treatment of hepatitis B and D
Phase 2
- Conditions
- Hepatitis B and D.Chronic viral hepatitis B with delta-agent
- Registration Number
- IRCT2017071128308N3
- Lead Sponsor
- Vice chancellor for research Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
chronic hepatitis B with HBsAg present at least 6 months before screening and infection with hepatitis D virus as anti-HDV positive antibodies for at least 3 months and positive for HDV-RNA in the screening period; HBeAg negative ; All women with fertility potential should have a negative pregnancy test before enrollment; ability to provide informed written consent to participate in the study.Exclusion criteria: untreated liver disease; co-infection with hepatitis C or HIV; Creatinine clearance <60 ml / min; Patients who are allergic to one of the Irbesartan components; Pregnancy and lactation; Patients with SBP <110 mm Hg or history of hypo tension at any time
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBsAg. Timepoint: Before study, 3 months after, 18 months after. Method of measurement: Blood test, in units per milliliter (IU / ml).
- Secondary Outcome Measures
Name Time Method